Dergiler / European Journal of Biology / 2020 / Cilt: 79 - Sayı: 2

Somatic Missense Mutations of Histone Variant H3.3 inCentral Nervous System Cancers

Sayfa
75–82
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Our results showed that H3.3 mutations detected in CNS cancers could affect the genomic distribution of post-translational modifications and histone variants, hence dramatically alter the gene expression profile and contribute to carcinogenesis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Histone variants are important modulators of chromatin functions.
📊
Temel Bulgular & Veri:Although some cancer-associated mutations of the histone variant H3.3 have been identified previously, a complete list of H3.3 mutations and their potential effects is yet to be uncovered.
💡
Sonuç & Katkı:Our results showed that H3.3 mutations detected in CNS cancers could affect the genomic distribution of post-translational modifications and histone variants, hence dramatically alter the gene expression profile and contribute to carcinogenesis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Histone variants are important modulators of chromatin functions. Studies have pointed out that epigenetic factors are often dysregulated in carcinogenesis. Although some cancer-associated mutations of the histone variant H3.3 have been identified previously, a complete list of H3.3 mutations and their potential effects is yet to be uncovered. Therefore, this study aims to identify the missense mutations of the histone variant H3.3 in central nervous system (CNS) cancers and to computationally predict their functional consequences on pathogenicity, protein stability and structure. Materials and Methods: A complete set of human H3.3 mutations was acquired from the COSMIC v90 database and missense mutations were selected. The potential effects of these mutations were assessed using PredictSNP2 and FATHMMXF. Structural outcomes were predicted using MUpro and HOPE servers. Results: We identified 45 unique missense H3.3 substitutions in several tissues including CNS. PredictSNP2 and FATHMM-XF predicted 17 and 42 mutations as deleterious respectively, most of which caused decreased protein stability. Amino acid alterations in CNS cancers were predicted to cause alterations of the 3D structure. Conclusion: Histone variants play significant roles in epigenetic regulation and are often mutated in cancers. Our results showed that H3.3 mutations detected in CNS cancers could affect the genomic distribution of post-translational modifications and histone variants, hence dramatically alter the gene expression profile and contribute to carcinogenesis.

🔖

Bu Makaleye Atıf Yap

SÜT, B. B. (2022). Somatic Missense Mutations of Histone Variant H3.3 inCentral Nervous System Cancers. European Journal of Biology, Cilt: 79 - Sayı: 2, 75–82. https://ajindex.com/articles/510577

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Kouzarides T. Chromatin modifications and their function. Cell 2007; 6(4): 693-705
  2. Albig W, Doenecke D. The human histone gene cluster at the D6S105 locus. Hum Genet 1997; 101: 284-94
  3. Yoda K, Ando S, Morishita S, Houmura K, Hashimoto K, Takeyasu K, et al. Human centromere protein A (CENP-A) can replace histone H3 in nucleosome reconstitution in vitro. Proc Natl Acad Sci USA 2000; 97: 7266-71
  4. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999; 146: 905-16
  5. Thakar A, Gupta P, Ishibashi T, Finn R, Silva-Moreno B, Uchiyama S, et al. H2A.Z and H3.3 histone variants affect nucleosome structure: biochemical and biophysical studies. Biochemistry 2009; 48(46): 10852-7
  6. Chakravarthy S, Gundimella SK, Caron C, Perche PY, Pehrson JR, Khochbin S, et al. Structural characterization of the histone variant macroH2A. Mol Cell Biol 2005; 25: 7616-24
  7. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131(6): 803-20. doi: 10.1007/s00401-016-1545-1
  8. McNeill KA. Epidemiology of brain tumors. Neurol Clin 2016; 34(4): 981-98.
  9. Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, et al. Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2015; 16(Suppl 10): x1-36
  10. Ajeawung NF, Wang HY, Gould P, Kamnasaran D. Advances in molecular targets for the treatment of medulloblastomas. Clin Invest Med 2012; 35(5): E246
  11. Coluccia D, Figuereido C, Isik S, Smith C, Rutka JT. Medulloblastoma: tumor biology and relevance to treatment and prognosis paradigm. Curr Neurol Neurosci Rep 2016; 16(5): 43. doi: 10.1007/ s11910-016-0644-7
  12. Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018; 19(6): 785-98. doi: 10.1016/S1470-2045(18)30242-0
  13. Park SH, Won J, Kim SI, Lee Y, Park CK, Kim SK, et al. Molecular testing of brain tumor. J Pathol Transl Med 2017; 51(3): 205-23. doi:10.4132/jptm.2017.03.08
  14. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von D